ME News: On August 28 (UTC+8), U.S. equities regained strength this week amid AI earnings reports and a rebound in crypto assets. As of the close of trading in New York on August 27, the S&P 500 rose approximately 0.7% for the week, while the Nasdaq advanced about 1.4%, with tech stocks once again leading market sentiment. NVIDIA’s better-than-expected earnings confirmed sustained demand for data centers, reviving sentiment across AI chips and computing infrastructure. Meanwhile, Bitcoin’s rebound combined with improving regulatory expectations drew renewed investor attention to crypto-linked stocks such as MSTR, CRCL, and PURR. In the pharmaceutical sector, Moderna strengthened on positive data from its mRNA cancer vaccine and FDA approval of a new COVID-19 vaccine, though commercialization outlooks remain divided. MSTR (up ~12.04% for the week): Strategy disclosed the sale of approximately $2 billion in shares, no additional BTC purchases, and the establishment of about $1.59 billion in USD cash. Following Bitcoin’s rebound, MSTR’s leveraged proxy characteristics have once again attracted capital, prompting the market to reprice its BTC treasury and cash buffer capacity. CRCL (up ~7.43% for the week): Bernstein maintained its “Outperform” rating and $140 price target for Circle, noting that USDC growth is not solely dependent on legislative catalysts; expansion of USDC supply, stablecoin payments, and on-chain capital market demand are supporting transaction volume, driving CRCL’s upward trend this week. PURR (up ~20.58% for the week): Momentum in the Hyperliquid ecosystem continues, with PURR trading on HYPE treasury holdings, improving regulatory sentiment, and DeFi beta exposure. After disclosing approximately $1.9 billion in HYPE holdings and a zero-debt balance sheet, PURR saw renewed volume and price appreciation on August 27, highlighting its small-cap, high-volatility profile. NVIDIA (up ~9.35% for the week): Q2 revenue reached $96.22 billion, with Q3 guidance of approximately $108 billion—both exceeding expectations; data center demand remains robust. Post-earnings, shares surged to $227.98, reigniting momentum in the AI chip sector and shifting market sentiment from concerns over peak AI capital expenditure to renewed belief in expanding demand. MRNA (up ~2.79% for the week): Positive melanoma mRNA vaccine data and FDA approval of a new COVID-19 vaccine provided catalysts, pushing the stock higher at times; however,分歧 remains regarding vaccine indications, commercialization pace, and earnings recovery expectations, resulting in a modest close after a pullback from weekly highs. (Source: BlockBeats)
MetaEra: NVIDIA Q2 Earnings Spark AI Trading; BTC Reserves and Stablecoins See Recovery
KuCoinFlashShare
Summary
According to MetaEra, the U.S. stock market rebounded on August 28 (UTC+8), with strong AI earnings and crypto recovery boosting sentiment. The S&P 500 rose 0.7%, while the Nasdaq climbed 1.4% for the week. NVIDIA reported Q2 revenue of $9.622 billion, surpassing expectations, and provided Q3 guidance of $10.8 billion, fueling optimism in the AI computing chain. Bitcoin’s rally and an improved regulatory outlook renewed interest in crypto-linked stocks such as MSTR, CRCL, and PURR. Trading volume on major exchanges increased, indicating stronger market participation. The Fear & Greed Index edged higher, reflecting a shift from caution to optimism. Moderna (MRNA) rose slightly on updated vaccine data, though commercial concerns remain.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.